Letter to Shareholders from the Chairman of the Board Ilya Shpurov
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) shares the following letter to shareholders from Chairman of the Board Ilya Shpurov: “It is my...
top of page
Поиск
Rafarma Signs Trilateral Investment Agreement Launching Tashkent Pharmaceutical Plant Build
The scientific and technical council of the Agency for the Development of the Pharmaceutical Industry of Uzbekistan recognized the...
Rafarma’s Global Pharmaceutical Strategy At A Glance
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is an international biotechnological and pharmaceutical company that combines research centers...
Rafarma To Expand Proton Therapy Centers
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that RAFA is in active meetings the City Scientific University of...
Rafarma and Haifa Technopark Enter Talks for Joint Venture
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that on April 26, 2021 the company entered negotiations and formed an...
Rafarma Embarks on Aggressive Global Partnerships Plan
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce its newly formulated strategies for aggressive global growth in...
Rafarma Signed an Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce its joint venture with the entity known as The Pharmaceutical Industry...
Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares,...
Rafarma Adds Prestigious New Board Chairman Ilia Shpurov
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov...
Rafarma Conducts Strategy Conference in Thailand for University and Hospital Joint Venture
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) reports that Mr. Anucha Pehtpeng, Rafarma’s Director of Thai Operations, represented the...
Rafarma Establishes Thailand Corporate Entity For Merger and Expansion Projects
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that it has established a new corporate entity in Thailand. The entity...
Rafarma - Biocogency Acquisition Progresses to Preparation of GAAP Financials
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to update its shareholders on the progress of its acquisition by the R. & D....
Letter to Shareholders Regarding Rafarma Acquisition by R. & D. Biocogency Laboratories Inc.
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) presents the following letter to Rafarma shareholders from CEO Vladimir Dolgolenko: Dear...
Rafarma to be Acquired by R. & D. Biocogency Laboratories Inc.
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that it has reached an agreement to be acquired by R. & D. Biocogency...
Rafarma Inks Deal For CBD-Infused Drink Product
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce finalization of the agreement with Destination Marketing Group Co. Ltd....
Rafarma Finalizes Announces New Product
Rafarma Pharmaceuticals, Inc. (OTC:RAFA) is happy to announce commencement of tests for its new product “HempySleep”. The product was...
Rafarma Finalizes Acquisition of Laskavy Patents, Prepared as Global Markets Reset
Rafarma Pharmaceuticals, Inc. (ORC: RAFA) is pleased to announce acquisition of all outstanding US and Australian patents from Vladislav...
Rafarma Establishes Advisory Board, Appoints First Member and Will Acquire Additional Patents
In establishing its Advisory Board, Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces the appointment of its first board member,...
Rafarma Has Agreed to Terms to Open its First Specialized Cannabis Spa in Europe
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that it has successfully completed negotiations with Albopark Ocio SL (a...
Shareholder Update Letter From Rafarma CEO V. Dolgolenko
Dear Shareholders, Since a recent teleconference call was held with shareholders there have been many things that have taken place. I...
bottom of page